Delayed Oral Estradiol Combined with Leuprolide Increases Endometriosis-Related Pain

Objectives: To determine if low-dose estrogen replacement can be added to GnRH agonist therapy after three months to reduce hypoestrogenic symptoms while allowing continued relief of pain in patients with endometriosis. Materials and Methods: Thirteen women with endometriosis and pain were treated with six months of leuprolide acetate in a prospective, randomized double-blind placebo controlled study. After three months of therapy, six subjects initiated oral estradiol 1 mg daily, and seven received an identical placebo. Results: Dysmenorrhea improved in both groups, and dyspareunia significantly improved in the GnRH agonist plus placebo group. The mean pain scores of the oral estrogen group tended to be higher than the placebo group, and hot flushes tended to be less severe with estrogen treatment. However, differences observed between the study and placebo groups did not reach statistical significance. Conclusion: In a prospective, randomized study, low-dose estrogen replacement increases endometriosis-related pain during GnRH agonist therapy. The study was terminated after the first 13 subjects due to the concerning trend toward recurrent symptoms in women who received oral estradiol during GnRH agonist therapy for endometriosis-related pain. With the trend toward increasing pain with estrogen add-back therapy, a larger study would not seem to be justifiable.

• Publication year

  2000

• Venue

  JSLS : Journal of the Society of Laparoendoscopic Surgeons

• Publication date

  2000-04-01

• Fields of study

  Medicine

• Identifiers
  PMID 10917114PMCID 3015370
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Endometriosis and the estrogen threshold theory. Relation to surgical and medical treatment.

  1998cited by this paper
• Leuprolide Acetate Depot and Hormonal Add‐Back in Endometriosis: A 12‐Month Study

  1998cited by this paper
• Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group.

  1997cited by this paper
• Low-Dose Esterified Estrogen Therapy: Effects on Bone, Plasma Estradiol Concentrations, Endometrium, and Lipid Levels

  1997cited by this paper
• Should add-back therapy for endometriosis be deferred for optimal results?

  1996cited by this paper
• Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial.

  1995cited by this paper
• Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis.

  1995cited by this paper
• Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain.

  1995cited by this paper
• Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results.

  1992cited by this paper
• Hormone treatment of endometriosis: the estrogen threshold hypothesis.

  1992cited by this paper
• GnRH analogues in the treatment of endometriosis — rationale and efficacy

  1991cited by this paper
• Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial.

  1988cited by this paper
• Unbalanced repeated-measures models with structured covariance matrices.

  1986cited by this paper
• Regression Models for Ordinal Data

  1980cited by this paper
• Conservative treatment of endometriosis: the effects of limited surgery and hormonal pseudopregnancy.

  1976cited by this paper
• Endometriosis of the Bowel: Role of Bowel Resection, Superficial Excision and Oophorectomy in Treatment

  1973cited by this paper

• Gonadotropin-releasing hormone analogues for endometriosis.

  2023cites this paper
• Advances in the medical management of bowel endometriosis.

  2020cites this paper
• Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis

  2020cites this paper
• Fellows 4-1-2018 Acute Gastric Volvulus Causing Splenic Avulsion and

  2019cites this paper
• Acute Gastric Volvulus Causing Splenic Avulsion and Hemoperitoneum

  2018cites this paper
• A ROLE FOR PHALERIA MACROCARPA (SCHEFF) BOERL. EXTRACTS IN THE MANAGEMENT OF WOMEN’S PATHOLOGICAL CONDITIONS: A RESEARCH REVIEW

  2017cites this paper
• Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy.

  2017cites this paper
• Медикаментозная терапия в лечении эндометриоза

  2016cites this paper
• Treatment of Endometriosis with the GnRHa Deslorelin and Add-Back Estradiol and Supplementary Testosterone

  2015cites this paper
• Measures used to assess chronic pelvic pain in randomized controlled clinical trials: a systematic review.

  2015cites this paper
• Systematic review of endometriosis pain assessment: how to choose a scale?

  2015cites this paper
• Clinical efficacy of add-back therapy in treatment of endometriosis: a meta-analysis

  2014cites this paper
• The use of gonadotropin releasing hormone analogues in adolescent and young patients with endometriosis

  2013cites this paper
• GnRH agonist therapy and the use of sex steroid add-back: improving the product

  2011cites this paper
• The efficacy and tolerability of short-term low-dose estrogen-only add-back therapy during post-operative GnRH agonist treatment for endometriosis.

  2011cites this paper
• Gonadotropin releasing hormone agonists: Expanding vistas

  2011cites this paper
• Optimizing Gonadotropin-Releasing Hormone Agonist Therapy in Women with Endometriosis

  2004cites this paper
• Estrous changes in vaginal nociception in a rat model of endometriosis.

  2003cites this paper
• Medical Therapy of Endometriosis

  2003cites this paper